Fatty Liver News and Research

Latest Fatty Liver News and Research

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

The international guidelines on the drug-based therapy of diabetes mellitus specify which factors need to be taken into account during treatment.

27 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions.

13 Mar 2014

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

A new study from the University of Washington has found that performance on Lumosity games can distinguish between patients with cirrhosis of the liver, pre-cirrhotic patients, and healthy controls. The study used Lumosity games as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis. The study is published in the March issue of the American Journal of Gastroenterology.

6 Mar 2014

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients

In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University-led team of researchers examined the metabolic breakdown that takes place in liver cells during late-stage cirrhosis and found clues that suggest new treatments to delay liver failure.

5 Mar 2014

Study shows fructose consumption does not contribute to non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease is the most common chronic liver disease in developed countries, affecting up to 30 per cent of their populations.

27 Feb 2014

New research shows that saturated fat builds more fat, less muscle than polyunsaturated fat

New research from Uppsala University shows that saturated fat builds more fat and less muscle than polyunsaturated fat. This is the first study on humans to show that the fat composition of food not only influences cholesterol levels in the blood and the risk of cardiovascular disease but also determines where the fat will be stored in the body.

25 Feb 2014

Health effects of childhood obesity may be long-lasting and profound

Childhood obesity rates have nearly tripled in the previous 30 years and researchers are asking the important question of how this epidemic will impact the future health of these obese children and public health in general. A University of Colorado Cancer Center article recently published in the journal Gerontology shows that even in cases in which obese children later lose weight, the health effects of childhood obesity may be long-lasting and profound.

14 Feb 2014

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.

11 Feb 2014

Researchers discover biological switch that regulates protein that causes fatty liver disease in mice

Studying a cycle of protein interactions needed to make fat, Johns Hopkins researchers say they have discovered a biological switch that regulates a protein that causes fatty liver disease in mice.

11 Feb 2014

Researchers find no benefit in replacing fructose with glucose

Researchers at St. Michael's Hospital have found there is no benefit in replacing fructose, the sugar most commonly blamed for obesity, with glucose in commercially prepared foods.

31 Jan 2014

Third-hand smoke as deadly as first-hand smoke

Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke.

30 Jan 2014

Johns Hopkins researchers discover epilepsy drug reduces obesity-related blood sugar levels

Johns Hopkins researchers have discovered that valproic acid, a widely prescribed drug for treating epilepsy, has the additional benefits of reducing fat accumulation in the liver and lowering blood sugar levels in the blood of obese mice.

30 Jan 2014

Omega-3 fatty acids especially DHA may have even wider range of biological impacts, shows study

A study of the metabolic effects of omega-3 fatty acids, especially DHA, concludes that these compounds may have an even wider range of biological impacts than previously considered, and suggests they could be of significant value in the prevention of fatty liver disease.

24 Jan 2014

Lack of SIRT1 protein in the liver leads to lower levels of liver FGF21

A new study led by Boston University School of Medicine demonstrates that the abnormal metabolism linked to obesity could be regulated in part by the interaction of two metabolic regulators, called the NAD-dependent deacetylase SIRT1 and fibroblast growth factor 21 (FGF21). Using experimental models, the researchers found that a lack of SIRT1 protein in the liver led to lower levels of a liver secreted protein FGF21, which resulted in an increased likelihood of developing fatty liver disease and obesity.

22 Jan 2014

AP-1 proteins modulate fat accumulation in liver, say researchers

Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.

8 Jan 2014

Researchers reveal how metabolic system breaks down in obesity

Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse obesity, Type 2 diabetes and fatty liver disease in humans.

20 Dec 2013

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

The first study of its kind, led by Melinda Sothern, PhD, CEP, Professor and Director of Behavioral and Community Health Sciences at LSU Health Sciences Center New Orleans School of Public Health, reveals that the same pro-inflammatory proteins linked to obesity and the metabolic syndrome in adults appear to protect children prior to puberty.

4 Dec 2013

Researchers discover how type 2 diabetes drug metformin actually works

Researchers from St. Vincent's Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX, a global leader in analytical technologies, played a critical role in the analysis that led to this breakthrough finding.

25 Nov 2013

Fatty Liver News and Research

Latest Fatty Liver News and Research

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients

Study shows fructose consumption does not contribute to non-alcoholic fatty liver disease

New research shows that saturated fat builds more fat, less muscle than polyunsaturated fat

Health effects of childhood obesity may be long-lasting and profound

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

Researchers discover biological switch that regulates protein that causes fatty liver disease in mice

Researchers find no benefit in replacing fructose with glucose

Third-hand smoke as deadly as first-hand smoke

Johns Hopkins researchers discover epilepsy drug reduces obesity-related blood sugar levels

Omega-3 fatty acids especially DHA may have even wider range of biological impacts, shows study

Lack of SIRT1 protein in the liver leads to lower levels of liver FGF21

AP-1 proteins modulate fat accumulation in liver, say researchers

Researchers reveal how metabolic system breaks down in obesity

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

Researchers discover how type 2 diabetes drug metformin actually works

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Fatty Liver News and Research

Latest Fatty Liver News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in